CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias

American Journal of Clinical Pathology

Volumn 140, Issue 3, 2013, Pages 370-378

  Chakhachiro, Zaher I ^a   Zuo, Zhuang ^a   Aladily, Tariq N ^a   Kantarjian, Hagop M ^a   Cortes, Jorge E ^a   Alayed, Khaled ^a   Nguyen, Martin H ^a   Medeiros, L Jeffrey ^a   Bueso Ramos, Carlos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; CD105; Endoglin; IDH2 mutation; Immunohistochemistry

Indexed keywords

ENDOGLIN; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CELL; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROID PRECURSOR CELL; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; STROMA CELL;

ACUTE MYELOID LEUKEMIA; CD105; ENDOGLIN; IDH2 MUTATION; IMMUNOHISTOCHEMISTRY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES;

EID: 84882795736     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPG8XH7ZONAKXK     Document Type: Article

References (40)

1. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem. 1990;265:8361-8364.
2. Perez-Gomez E, Del Castillo G, Juan Francisco S, et al. The role of the TGF-beta coreceptor endoglin in cancer. Sci World J. 2010;10:2367-2384.
3. Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931-1937.
4. Lebrin F, Mummery CL. Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med. 2008;18:25-32.
5. Fonsatti E, Del Vecchio L, Altomonte M, et al. Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol. 2001;188:1-7.
6. Rosen LS, Hurwitz HI, Wong MK, et al. A phase I first-inhuman study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18:4820-4829.
7. Rokhlin OW, Cohen MB, Kubagawa H, et al. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol. 1995;154:4456-4465.
8. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
9. Liang M, Han X, Vadhan-Raj S, et al. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod Pathol. 2010;23:381-391.
10. Oyarzo MP, Lin P, Glassman A, et al. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol. 2004;122:348-358.
11. Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135:35-45.
12. Bains A, Luthra R, Medeiros LJ, et al. FLT3 and NPM1 mutations in myelodysplastic syndromes: frequency and potential value for predicting progression to acute myeloid leukemia. Am J Clin Pathol. 2011;1:62-69.
13. Zuo Z, Medeiros LJ, Chen Z, et al. Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. PLoS One. 2012;7:e41485.
14. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;12:3679-3687.
15. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;13:3088-3091.
16. Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;15:2529-2537.
17. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;16:1617-1628.
18. Catchpoole D, Lail A, Guo D, et al. Gene expression profiles that segregate patients with childhood acute lymphoblastic leukaemia: an independent validation study identifies that endoglin associates with patient outcome. Leuk Res. 2007;31:1741-1747.
19. Della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20:549-555.
20. Lo Pardo C, Altomonte M, Boccuni P, et al. CD105 workshop: expression of CD105 on acute leukemia blast cells: application for minimal residual disease detection. In: Kishimoto T, Kikutani H, von dem Borne AEGK, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland; 1998:711-712.
21. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16:387-397.
22. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:2348-2355.
23. Pardanani A, Lasho TL, Finke CM, et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24:1146-1151.
24. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094-1096.
25. Lin J, Yao DM, Qian J, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2010;91:519-525.
26. Chotirat S, Thongnoppakhun W, Promsuwicha O, et al. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol. 2012;5:5.
27. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116:2122-2126.
28. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474-478.
29. Devillier R, Gelsi-Boyer V, Brecqueville M, et al. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Am J Hematol. 2012;87:659-662.
30. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079-1089.
31. Andersson AK, Miller DW, Lynch JA, et al. IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011;25:1570-1577.
32. Henriksen R, Gobl A, Wilander E, et al. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest. 1995;73:213-220.
33. Liu Y, Jovanovic B, Pins M, et al. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene. 2002;21:8272-8281.
34. Craft CS, Romero D, Vary CP, et al. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene. 2007;26:7240-7250.
35. Kassouf W, Ismail HR, Aprikian AG, et al. Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer Prostatic Dis. 2004;7:105-110.
36. Bock AJ, Tuft Stavnes H, Kaern J, et al. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol. 2011;32:589-596.
37. Davidson B, Stavnes HT, Forsund M, et al. CD105 (endoglin) expression in breast carcinoma effusions is a marker of poor survival. Breast. 2010;19:493-498.
38. Borges L, Iacovino M, Mayerhofer T, et al. A critical role for endoglin in the emergence of blood during embryonic development. Blood. 2012;119:5417-5428.
39. Pierelli L, Bonanno G, Rutella S, et al. CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma. 2001;42:1195-1206.
40. Calabrò L, Fonsatti E, Bellomo G, et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol. 2003;194:171-175.